Entry of SARS-COV-2 into mammalian cells is mediated by angiotensin-converting enzyme 2 (ACE2). This binding and consequent ACE2 endocytosis have potential to disrupt blood pressure regulation by interfering with ACE2-mediated cleavage of angiotensin II (AngII). Now, Swartz and colleagues suggest that SARS-CoV-2 infection might also dysregulate vascular tension in patients with severe COVID-19 by promoting the formation of anti-AngII autoantibodies.
The researchers detected anti-ACE2 antibodies in serum from hospitalized patients with COVID-19, and the antibody levels correlated strongly with blood pressure dysregulation and disease severity (based on blood oxygenation levels). Mouse monoclonal anti-AngII antibodies cross-reacted with recombinant SARS-CoV-2 spike protein, indicating that epitope mimicry might contribute to the generation of autoantibodies in infected individuals. In vitro, monoclonal anti-ACE2 antibodies interfered with binding of AngII to AngII receptor type 1, suggesting antagonism of AngII function.
References
Original article
Briquez, P. S. et al. Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity. Sci. Adv. 8, eabn3777 (2022)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, M. AngII autoantibodies after SARS-CoV-2 infection. Nat Rev Nephrol 18, 743 (2022). https://doi.org/10.1038/s41581-022-00650-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-022-00650-4